The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Sat, May 28, 2022 | 06:18
Health & Science
Korea to secure oral COVID-19 medications for 404,000 patients
Posted : 2021-10-29 14:13
Updated : 2021-10-30 17:32
Print Preview
Font Size Up
Font Size Down
This Feb. 5 file photo shows the Pfizer logo displayed at the company's headquarters in New York. AP-Yonhap
This Feb. 5 file photo shows the Pfizer logo displayed at the company's headquarters in New York. AP-Yonhap

South Korea plans to secure enough oral COVID-19 medications to treat some 404,000 infected patients from global drugmakers and distribute them starting in the first quarter of next year, the government said Friday.

The government said it signed a pre-purchase contract with U.S. pharmaceutical giant Pfizer Inc. this month to buy enough medications to prescribe to 70,000 patients, an official from the Central Disaster and Safety Countermeasure Headquarters said.

Last month, the government also clinched a deal with global drugmaker MSD to purchase its oral COVID-19 medication for 200,000 people.

The government said it will speed up efforts to secure the amount for the remaining 134,000 people by closely monitoring the clinical progress of multinational drugmakers and authorities' approval.

The oral medications will be used to treat those with underlying illnesses, elderly patients and others with acute COVID-19 symptoms. (Yonhap)


 
  • [SPECIAL REPORT] Asylum-seekers create Myanmartown from scratch in Bupyeong
  • S. Korean volunteer fighter in Ukraine returns home with knee injuries
  • Koreans ready to flock to Japan as tourism resumes in June
  • Presidential security team misplaces live bullets
  • UN Security Council fails to pass N. Korea resolution due to opposition from China, Russia
  • Early voting for local elections kicks off
  • Trade deficit feared to become long-lasting trend
  • Sex slavery activist Youn under fire for not sharing details of settlement with victims
  • POSCO Chemical, GM pick Quebec as site for $327 mil. joint cathode plant
  • WHO assembly slams Russian attacks on Ukraine health facilities
  • Disney+ original 'Kiss Sixth Sense' to offer high-spirited, fantasy rom-com Disney+ original 'Kiss Sixth Sense' to offer high-spirited, fantasy rom-com
  • [INTERVIEW] German professor hopes to boost appreciation for Korean traditional music [INTERVIEW] German professor hopes to boost appreciation for Korean traditional music
  • 'The Roundup' becomes most-watched Korean film in pandemic era 'The Roundup' becomes most-watched Korean film in pandemic era
  • [INTERVIEW] Korea needs more small-sized concert venues: Prof. Lee Gyu-tag [INTERVIEW] Korea needs more small-sized concert venues: Prof. Lee Gyu-tag
  • Korean films make splash at Cannes Film Festival Korean films make splash at Cannes Film Festival
DARKROOM
  • 75th Cannes Film Festival

    75th Cannes Film Festival

  • People in North Korea trapped in famine and pandemic

    People in North Korea trapped in famine and pandemic

  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group